Bayer cuts four programs amid a 'slow start' to the year
Bayer announced a handful of pipeline cuts in its quarterly earnings report last week, as CEO Werner Baumann revealed the quarter “came in soft” compared to last year’s performance.
The culls include two Phase II programs, a BDKRB1 receptor antagonist for neuropathic pain, and runcaciguat, in development for chronic kidney disease. The BDKRB1 receptor plays a role in pain perception, and Bayer’s candidate, BAY 2395840, came out of a research alliance with Evotec. The company also said it’s discontinuing a Phase I program studying BAY 2395840 in endometriosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.